Sugi Predict

Sugi Predict / Compounds / SCHEMBL1670382

SCHEMBL1670382

SCHEMBL1670382

O=C(Cl)c1cc(I)ccc1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN2 P17706 2/20 0.37
▸ PTPN1 P18031 2/20 0.37
▸ PTPN6 P29350 2/20 0.37
▸ PTPRC P08575 1/20 0.37
▸ PTPRA P18433 1/20 0.37
▸ PTPRB P23467 1/20 0.37
▸ PTPRE P23469 1/20 0.37
▸ AR P10275 2/20 0.36
▸ ABL1 P00519 1/20 0.35
▸ BCR P11274 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ GSK3B P49841 1/20 0.32
▸ TPMT P51580 1/20 0.32
▸ ERN1 O75460 1/20 0.31
▸ CA1 P00915 2/20 0.31
▸ CA2 P00918 2/20 0.31
▸ HPGD P15428 2/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203554 0.81 PTPN1 (0.50) PTPN2PTPN1PTPN6PTPRCPTPRA
SCHEMBL26930859 0.79 PTPRC (0.37) PTPN2PTPN1PTPN6PTPRCPTPRA
SCHEMBL8282570 0.79 ERN1 (0.42) PTPN2PTPN1PTPN6PTPRCPTPRA
SCHEMBL706916 0.78 ALOX15 (0.48) PTPN2PTPN1PTPN6ALDH1A1ALOX15
SCHEMBL27454155 0.78 PTPN2 (0.39) PTPN2PTPN1PTPN6PTPRCPTPRA
SCHEMBL23242473 0.77 AR (0.47) PTPN2PTPN1PTPN6PTPRCPTPRA
SCHEMBL1669829 0.77 ALDH1A1 (0.47) ALDH1A1CA1CA2HPGDNPC1
SCHEMBL2266803 0.77 MAPT (0.38) ALDH1A1ALOX15CA1CA2NPC1
SCHEMBL1934879 0.77 ALDH1A1 (0.42) PTPN2PTPN1PTPN6PTPRCPTPRA
SCHEMBL3736638 0.76 PTPRC (0.35) PTPN2PTPN1PTPN6PTPRCPTPRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49080-E1 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2022-05-24 — — US disclosed
CN-113004349-A Preparation method of SGLTs inhibitor and key intermediate thereof 上海研健新药研发有限公司 2021-06-22 — — CN disclosed
EP-3056507-B1 C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF YOUNGENE THERAPEUTICS CO LTD (CN) 2020-09-23 — — EP disclosed
EP-3056507-B1 C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF YOUNGENE THERAPEUTICS CO LTD (CN) 2020-09-23 — — EP disclosed
CN-107311992-B C-aryl glucoside derivative, preparation method and application thereof in medicine 上海研健新药研发有限公司 2020-08-18 — — CN disclosed
US-10011627-B2 C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof YOUNGENE THERAPEUTICS CO., LTD (CN) 2018-07-03 — — US disclosed
US-10011627-B2 C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof YOUNGENE THERAPEUTICS CO., LTD (CN) 2018-07-03 — — US disclosed
CN-105518014-B C-aryl glucoside derivative, preparation method and application thereof in medicine 上海研健新药研发有限公司 2018-03-23 — — CN disclosed
US-9895389-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2018-02-20 — — US disclosed
US-9895389-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2018-02-20 — — US disclosed
US-20110171159-A1 Glycoside Derivatives and Uses Thereof NOVARTIS AG (CH) 2011-07-14 — — US disclosed
WO-2011048112-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2011-04-28 — — WO disclosed
US-7829737-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof CEPTYR, INC. (US) 2010-11-09 — — US disclosed
US-20090131374-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CEPTYR, INC. (US) 2009-05-21 — — US disclosed
US-7504389-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof CEPTYR, INC. (US) 2009-03-17 — — US disclosed
US-20080161592-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CEPTYR, INC. (US) 2008-07-03 — — US disclosed
CN-101094677-A Protein tyrosine phosphatase inhibitors and methods of use thereof CEPTYR INC (US) 2007-12-26 — — CN disclosed
EP-1812012-A2 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Ceptyr, Inc. (US) 2007-08-01 — — EP disclosed
US-20060142250-A1 Protein tyrosine phosphatase inhibitors and methods of use thereof FALCON TECHNOLOGY PARTNERS L.P. 2006-06-29 — — US disclosed
WO-2006055525-A2 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CEPTYR, INC. (US) 2006-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011627-B2 C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof SLC5A1, SLC5A2, UGGT1 PTPN2 553/4885PTPN1 479/4885PTPN6 539/4885
US-20080161592-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PPM1B, PTPN1, PTPN5 PTPN2 5/4885PTPN1 2/4885PTPN6 10/4885
US-20060142250-A1 Protein tyrosine phosphatase inhibitors and methods of use thereof PPM1B, PTPN1, PTPN5 PTPN2 5/4885PTPN1 2/4885PTPN6 10/4885
US-20110171159-A1 Glycoside Derivatives and Uses Thereof SLC5A1, SLC5A2, SLC2A1 PTPN2 767/4885PTPN1 723/4885PTPN6 704/4885
US-20090131374-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PPM1B, PTPN1, PTPN5 PTPN2 5/4885PTPN1 2/4885PTPN6 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.